Mylan and Biocon announce positive CHMP opinion for Ogivri®, Biosimilar Trastuzumab
Mylan and Biocon announced that the EMA's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Ogivri®, a biosimilar to Roche's Herceptin® (trastuzumab). The decision on approval is expected by the end of 2018. October 19, 2018